Nature Communications (Aug 2024)

Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM

  • Fumiaki Ito,
  • Ziyuan Li,
  • Leonid Minakhin,
  • Gurushankar Chandramouly,
  • Mrityunjay Tyagi,
  • Robert Betsch,
  • John J. Krais,
  • Bernadette Taberi,
  • Umeshkumar Vekariya,
  • Marissa Calbert,
  • Tomasz Skorski,
  • Neil Johnson,
  • Xiaojiang S. Chen,
  • Richard T. Pomerantz

DOI
https://doi.org/10.1038/s41467-024-51351-4
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 13

Abstract

Read online

Abstract DNA polymerase theta (Polθ) is a DNA helicase-polymerase protein that facilitates DNA repair and is synthetic lethal with homology-directed repair (HDR) factors. Thus, Polθ is a promising precision oncology drug-target in HDR-deficient cancers. Here, we characterize the binding and mechanism of action of a Polθ helicase (Polθ-hel) small-molecule inhibitor (AB25583) using cryo-EM. AB25583 exhibits 6 nM IC50 against Polθ-hel, selectively kills BRCA1/2-deficient cells, and acts synergistically with olaparib in cancer cells harboring pathogenic BRCA1/2 mutations. Cryo-EM uncovers predominantly dimeric Polθ-hel:AB25583 complex structures at 3.0-3.2 Å. The structures reveal a binding-pocket deep inside the helicase central-channel, which underscores the high specificity and potency of AB25583. The cryo-EM structures in conjunction with biochemical data indicate that AB25583 inhibits the ATPase activity of Polθ-hel helicase via an allosteric mechanism. These detailed structural data and insights about AB25583 inhibition pave the way for accelerating drug development targeting Polθ-hel in HDR-deficient cancers.